GSK’s (GSK) “Buy” Rating Reaffirmed at Shore Capital

Shore Capital reissued their buy rating on shares of GSK (LON:GSK) in a report issued on Thursday, Marketbeat Ratings reports.

A number of other research analysts have also commented on GSK. JPMorgan Chase & Co. increased their price objective on GSK from GBX 1,400 to GBX 1,500 and gave the company an “underweight” rating in a research report on Friday, November 7th. Jefferies Financial Group raised their price target on GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a report on Monday, November 3rd. Finally, Berenberg Bank lifted their price objective on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research report on Monday, November 24th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of GBX 1,762.

GSK Trading Up 0.1%

GSK opened at GBX 1,902.75 on Thursday. GSK has a 1-year low of GBX 1,242.50 and a 1-year high of GBX 1,909.73. The stock has a market capitalization of £76.76 billion, a PE ratio of 14.31, a PEG ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The firm has a 50-day moving average price of GBX 1,807.64 and a two-hundred day moving average price of GBX 1,597.30.

GSK (LON:GSK) last released its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities analysts anticipate that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Transactions at GSK

In other news, insider Wendy Becker purchased 441 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were acquired at an average cost of GBX 1,809 per share, for a total transaction of £7,977.69. Also, insider Jonathan Symonds acquired 1,650 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were purchased at an average price of GBX 1,810 per share, with a total value of £29,865. Corporate insiders own 0.20% of the company’s stock.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Bepirovirsen shows promising results in chronic hepatitis B trials, hitting study goals in two trials — a potential long-term commercial opportunity if further development/approval proceeds. GSK’s bepirovirsen shows promising results in chronic hepatitis B trials
• Positive Sentiment: Shingrix advances: European Commission approval for a prefilled syringe format and a separate approval to present Shingrix data — supports ongoing sales momentum and product lifecycle management for an important vaccine franchise. GSK’s Shingrix prefilled syringe receives European Commission approval
• Positive Sentiment: Japan’s MHLW approves Exdensur — a regulatory win that expands GSK’s marketed product base and supports near‑term revenue in Japan. GSK announces approval of Exdensur by Japan’s MHLW
• Positive Sentiment: Jefferies and Shore Capital reaffirm buy ratings (Jefferies sets a GBX 2,100 price target) — positive analyst support could bolster investor interest and help sustain upside momentum. Broker ratings (Jefferies, Shore Capital)
• Neutral Sentiment: Valuation review after strong 1‑year shareholder returns — useful context for investors weighing current price versus fundamentals, not an immediate catalyst. GSK valuation check
• Neutral Sentiment: Real estate transaction: vacant former GSK building sold for $52M — non-operational corporate real estate news with limited impact on core pharmaceuticals business. Vacant former GSK building at the Navy Yard sells for $52M
• Negative Sentiment: JPMorgan reaffirmed an “underweight” rating — a high-profile negative analyst stance that can pressure sentiment and cap upside. Broker ratings (JPMorgan)
• Negative Sentiment: Barclays downgraded GSK — another downgrade adding to mixed broker views and raising near‑term downside risk from sentiment-driven selling. Barclays downgrades GSK

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.